一项干预性研究,比较他非诺喹 (TQ) 和伯氨喹 (PQ) 与氯喹 (CQ) 合用治疗 2 岁及以上印度参与者间日疟原虫疟疾的疗效和安全性
一项随机、开放标签、多中心、干预性 3 期疗效研究。印度参与者(儿童和成人)中他非诺喹与伯氨喹(均与氯喹合用)根治(预防复发)间日疟原虫疟疾的安全性
The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
研究联系人备份
- 姓名:EU GSK Clinical Trials Call Center
- 电话号码:+44 (0) 20 89904466
- 邮箱:GSKClinicalSupportHD@gsk.com
学习地点
-
-
-
Ahmedabad、印度、380008
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Leena Dabhi
-
Bikaner、印度、334001
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Sanjay Kumar Kochar
-
Kolkata、印度、700073
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Arunansu Talukdar
-
Mumbai、印度、400012
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Nithya Gogtay
-
Surat、印度、395004
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Shailesh Jethwa
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Males and females >=2 years of age and under (<) 65 years of age, weighing >10 kg.
-
The participant has a positive malarial smear for P. vivax with a parasite density of >100/microliter and <100,000/microliter.
-
The participant has a screening Hb value >8 g/dL.
-
The participant has an axillary temperature of 37.5°C or history of fever 48 hours before recruitment.
-
The participant has a G6PD value (measured using the SD Biosensor STANDARDTM G6PD test) 6.1 units/gram (U/g) Hb for G6PD activity (6.1 U/g Hb cut-off is applicable for both males and females).
-
A female participant is eligible to participate if she is not pregnant or breastfeeding, and if one of the following conditions applies:
- Is a woman of non-childbearing potential (WONCBP) as defined in
- Is a Women of Childbearing Potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, during the study intervention period and for at least 90 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
-
A WOCBP must test negative on a highly sensitive pregnancy test (urine or serum as required by local regulations) before the first dose of study intervention.
-
The participant is willing and able to comply with the procedures described in the study protocol. The participant or parent/legal guardian, as applicable, has given written informed, dated consent; and the participant has given written assent, if applicable, to participate in the study.
Exclusion Criteria:
-
The participant has severe P. vivax malaria as defined by WHO criteria [WHO, 2023].
-
The participant has a mixed malaria infection (identified by a malarial smear).
-
The participant has a condition that may affect absorption of study medication, such as severe vomiting (no food or inability to take food during the previous 8 hours).
-
The participant has a history of porphyria, psoriasis, or epilepsy.
-
The participant has a history of allergy, intolerance to or a known contraindication to the use of mefloquine (or other aryl amino alcohol drugs), chloroquine, tafenoquine, primaquine, any other 4- or 8-AQ or any of their respective excipients.
-
The participant has received treatment with any investigational drug within 30 days of study entry, or within 5 half-lives, whichever is longer.
-
The participant has previously enrolled in this study.
-
The participant has a recent history of illicit drug abuse or heavy alcohol intake that in the opinion of the investigator could compromise full participation in the study or adherence to study procedures.
-
Participants with a current or past history of serious psychiatric disorders.
-
The participant has a clinically significant concurrent illness (e.g., pneumonia, tuberculosis, meningitis, septicemia, dengue, coagulopathy, severe hemorrhage, or febrile convulsions prior to consent) or a pre-existing condition (e.g., renal disease, malignancy, or severe malnutrition according to WHO child growth standards) or systemic disease predisposing patients to suffer from granulocytopenia, such as rheumatoid arthritis and lupus erythematosus or severe ocular disease.
-
The participant is known to be HIV-infected and/or is currently on antiretroviral therapy.
-
The participant is regularly using drugs with hemolytic potential.
-
The participant has a QT corrected by Fridericia's formula (QTcF) >450 msec, evidence of bradycardia (<50 beats per min) or ventricular arrhythmias on the screening ECG, a history of cardiac disease (e.g., myocardial infarction, congenital heart disease, or arrhythmia), hypokalemia (<2.9 millimoles per liter [mmol/L]) or hyperkalemia (>=6.0 mmol/L) at Screening.
-
The participant has taken drugs with antimalarial activity (e.g., artemisinin-based combination therapies, mefloquine, primaquine, chloroquine, tafenoquine or any other 4-AQ) within 30 days prior to study entry.
-
The participant has taken or will likely require during the study the use of:
- Histamine-2 blockers (restricted to first 3 days whilst receiving CQ)
- Antacids (restricted to first 3 days whilst receiving CQ)
- Drugs of the biguanide class (i.e., phenformin, metformin, buformin)
- Anti-arrhythmic agents (i.e., dofetilide, procainamide, pilsicainide)
- Medications that prolong the QTc interval
-
The participant has liver transaminases (ALT/AST) >2 times the upper limit of normal (ULN).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:TQ/CQ
Participants in this group receive a single dose of TQ on Day 1 or Day 2 and a single dose of CQ daily, on Days 1 to 3. |
A single dose of TQ will be administered orally on Day 1 or Day 2. A single dose of CQ will be administered orally, daily, on Days 1 to 3. |
|
有源比较器:PQ/CQ
Participants in this group receive a single dose of PQ daily from Day 1 or 2, up to Day 14 (or Day 15 if PQ started on Day 2) and a single dose of CQ daily, on Days 1 to 3. |
A single dose of CQ will be administered orally, daily, on Days 1 to 3. A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2). |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants remaining recurrence-free during the 6 months post-treatment and have a negative blood smear at the Month 6 (end of study [EOS]) visit
大体时间:Up to Month 6
|
Two consecutive negative blood smears between Day 2 and Day 8, no positive blood smear for P. vivax parasites at any point during the 6-month follow-up period, and a negative P. vivax smear at the 6-month assessment. |
Up to Month 6
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
死亡人数
大体时间:直至第 6 个月
|
直至第 6 个月
|
|
|
实验室参数满足 >= AIDS 部门 (DAID) 3 级标准
大体时间:直至第 6 个月
|
直至第 6 个月
|
|
|
生命体征参数满足 >=DAIDs 3 级标准
大体时间:直至第 6 个月
|
直至第 6 个月
|
|
|
每次研究访视时血液学参数相对于基线的变化(网织红细胞百分比)
大体时间:第 5、8、15、29、60、90、120、150 和 180 天
|
第 5、8、15、29、60、90、120、150 和 180 天
|
|
|
Number of participants with clinically relevant hemolysis change from baseline
大体时间:Up to Day 14
|
A decrease in hemoglobin of greater than or equal to (>=) 30% or greater than (>) 3g/deciliter (dL) from baseline; or an overall drop in hemoglobin below 6.0 g/dL or complications thereof (e.g., required transfusions, acute renal failure) are considered clinically relevant hemolysis changes. |
Up to Day 14
|
|
Time to recurrence of P. vivax malaria
大体时间:Up to Month 6
|
Recurrence is defined as a positive blood smear for P. vivax parasites within the 6-month follow-up period, after clearance of blood-stage parasitemia. |
Up to Month 6
|
|
Number of participants with treatment emergent adverse events (TEAEs) up to Month 6
大体时间:Up to Month 6
|
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with TEAEs meeting >= Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 criteria
大体时间:Up to Month 6
|
Severity was graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening, Grade 5-Death. |
Up to Month 6
|
|
Number of participants with drug related TEAEs
大体时间:Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with serious AEs (SAEs)
大体时间:Up to Month 6
|
A SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization or result in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant. |
Up to Month 6
|
|
Number of participants with AEs resulting in treatment discontinuation
大体时间:Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with AEs leading to study withdrawal
大体时间:Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with AEs considered to be hematologically related
大体时间:Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Liver chemistry changes meeting Hy's criteria
大体时间:Up to Month 6
|
Hy's criteria cases were defined as any elevated alanine aminotransferase (ALT) >=3 times upper limit of normal (ULN) and total bilirubin >=2 times ULN or ALT >=3 times ULN and international normalized ratio (INR) >1.5. |
Up to Month 6
|
|
Number of participants with TEAEs up to Week 4
大体时间:Up to Week 4
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Week 4
|
|
Change from baseline at each study visit for clinical chemistry parameters (ALT, AST, ALP)
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) is measured in international units/liter (IU/L). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for clinical chemistry parameters (CPK)
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for creatine phosphokinase (CPK) is measured in units per liter (U/L). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for clinical chemistry parameters (total bilirubin, indirect bilirubin, blood urea nitrogen [BUN]/Urea, and serum creatinine)
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Clinical chemistry parameters are measured in milligrams per decilitre (mg/dL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for clinical chemistry parameters (serum electrolytes)
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for serum electrolytes is measured in millimoles per liter (mmol/L). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (platelet count)
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Platelets are measured in number of platelets per microliter (µL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (red blood cell [RBC] count)
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for RBC is measured in millions of cells per microliter (number of RBCs x10^6/µL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (mean corpuscular volume [MCV])
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for MVC is measured in femtoliters (fL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (mean corpuscular hemoglobin [MCH])
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for MCH is measured in picograms (pg) per cell. |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (white blood cell count [WBC] with differential)
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for neutrophils, lymphocytes, monocytes, eosinophils and basophils is presented as a count, which measures a percentage (%) of the WBC. |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (hemoglobin)
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Hemoglobin is measured in grams per deciliter (g/dL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (hematocrit)
大体时间:At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Hematocrit is measured in volume percentage (%) of RBC in blood. |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 208550
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
IPD 共享时间框架
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD 共享访问标准
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.